Member Info for B2HS2L

I am looking for evidence of income from Royalties and Agreements in the March 23rd 2017 Prelim. results. Below is an extract from the FUM Interim Results published 13.09.2016. Bottom of Page 3 - "Commercial manufacture of product for the launch of CSD500 in the first Middle East country, where regulatory approval has already been granted, has already taken place with the launch expected later this year. The initial royalty payment has already been received for this and will be recognised upon launch. We anticipate further launches of the product in other territories during 2017." CSD500 recently launched in Saudi-Arabia, so I am assuming the royalty payments will be visible in the accounts. Hopefully there will be info about amount of initial sales. 1) It will show the market FUM has a royalties income stream for the first time. 2) It might prompt the business press to articulate more often on FUM progress, and help to stabilise /improve the share price. Lets hope the market likes the numbers.

Looks good goldust. If you wanted to add in USA inflation between 2008 and 2016 = 14.8% total. source: http://www.usinflationcalculator.com/inflation/historical-inflation-rates/. Just my two cents.

I'm hoping we will get a few numbers for royalties and licences on March 23rd. That's when I expect a big change, up or down, depending on whether the market 'likes' what it is seeing.

Chrisjc, - there is no evidence FUM has any in-house marketing expertise. Its a fact that there was minimal marketing effort in the Blue Diamond product release in Holland / Belgium. It is also a fact that the board makes no pretence of having Marketing expertise. I cannot find any documentation on the website that can provide evidence of marketing spend. I prefer to believe the board wanted to get user feedback, particularly of the adverse kind, rather than shout the new condom benefits from the rooftops. As an R&D company, FUM don't need Marketing expertise as they who have a service or product to sell, nor will it be required in future. FUM features very little in the business press, and the lack of spreading the news about FUM and its revolutionary products is partially the reason why the share price has reduced by >15% since institutions invested recently. The blame for that smack in the eye for investors is with the board, no body else is employed there. Zwartkopf reports the company were 'disappointed with the sp slide', and that the company wanted to attract more Institutional Investors. LSE were on the phone for a quote as to why the sp slump. Letting the share price slide will not assist in achieving these aims. More effort is required on showcasing the benefits of the FUM portfolio, with an accent on the near future, the nearly complete regulatory aspects of some products, the licensing agreements freshly signed, some idea of the royalties would be nice, and I expect we will get this on March 23rd. Everyone outside of FUM thinks it is a loss making R&D establishment. They need to be educated that is no longer the case, with news of royalty and licence payments, then we will see sp stabilisation if not increase. We'll see what the company is willing to provide soon enough.

Zwarts, - Can you phone the company more often? Your massage has had a remarkable affect on the share price today.

Bruce, - A timely reminder, and possibly why sp has rallied recently. I'm more used to seeing MM's increasing the supply by reducing the share price.

Took your advice and topped up, - after sp hit an area of support of course. I suspect the share price may fall further if MM's require more shares and can't find those willing to sell. Can't think of another reason why sp would fall at present. Absolutely a no brainer, - I'm hoping all my birthdays have come at once.

The Futuramedical website ( http://www.futuramedical.com/content/company/our_board.asp ) states the present responsibilities and past experience of the board. Unsurprisingly 'Sales' or 'Marketing' is not mentioned.. 9 people are employed at Futura, maybe the cleaner has a 'secondary duty', and is attending night school. It explains why the sales and marketing effort applied to the launch of Blue Diamond in Holland / Belgium was visible by its absence. Still, onwards and upwards eh.

So far, there has been only so much news, and more good news expected. But the only news which has moved the share price very far is that which concerns the gel. Blue Diamond, and Pain Killer news has not tended to move the share price much. As we are not expecting any news soon, concerning the work in progressing the gel to market, sp might slump further, until those holding shares are coerced to sell. This might get ugly, and some will take the view that it's better to sell and buy back later, - if they can, - it might be a risk worth taking. I would not want to be in their shoes come a takeover bid. Everyone thinks the gel will be a new and better Viagra. If this is so, Large Pharma's will not want such a large cash cow, available without prescription, in a competitors catalogue. On this basis I am waiting to find which large Pharma comes up with an acceptable bid before one of their peers does. This could of course happen anytime. My view is to sit tight & not to sell, even if sp approaches early September levels, and to seek small purchases when sp shows signs of plateauing.

It does my head in too. I remain invested in the hope that a Mega-pharma will buy the entire company. That is the only way I see at present that a fair price is going to be achieved for FUM. I assume this becomes more likely the closer the gel is ready for launch. I assume the board is ready with a fair valuation for FUM when the time comes. Only news of the jel will shift the sp significantly, all other product news will not have the same effect.

It's good to see investment companies starting to buy shares in such quantity. This might snowball, as each is conscious of where peers are investing, and particularly investment timing. When you consider their decision to prioritise FUM share purchase at the expense of making other investments, they are either late to the table, (or why buy so many shares at once?), or good news for the s.p. is due very short term. - or both. They are pressured to see value being generated short term, so presumably they agree that Futura's time is nigh, and with the current attractive s.p. 'supported' by recent events, investment risk is reduced. James B - What news from the negotiating table? - We don't need a miracle, just a few agreement or royalty signatures.